The association of IFI27 expression and fatigue intensification during localized radiation therapy: Implication of a para-inflammatory bystander response

International Journal of Molecular Sciences

Volumn 14, Issue 8, 2013, Pages 16943-16957

  Hsiao, Chao Pin ^a,b   Araneta, Maria ^b   Wang, Xiao Min ^b   Saligan, Leorey N ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF NURSING RESEARCH   (United States)

Author keywords

Fatigue; Gene expression; Interferon; Prostate cancer; Radiation

Indexed keywords

ALPHA INTERFERON; INTERFERON ALPHA INDUCIBLE PROTEIN 27; UNCLASSIFIED DRUG;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BYSTANDER EFFECT; CANCER FATIGUE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DISEASE SURVEILLANCE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTERNAL BEAM RADIOTHERAPY; GENE EXPRESSION REGULATION; HUMAN; IFI27 GENE; IMMUNE RESPONSE; MALE; MICROARRAY ANALYSIS; ONCOGENE; PROSTATE CANCER; PROSTATECTOMY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

AGED; BYSTANDER EFFECT; CASE-CONTROL STUDIES; FATIGUE; HUMANS; INFLAMMATION MEDIATORS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; RADIATION INJURIES; TRANSCRIPTOME;

EID: 84882725717     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140816943     Document Type: Article

References (42)

1. Wong, W.W.; Vora, S.A.; Schild, S.E.; Ezzell, G.A.; Andrews, P.E.; Ferrigni, R.G.; Swanson, S.K. Radiation dose escalation for localized prostate cancer: Intensity-modulated radiotherapy versus permanent transperineal brachytherapy. Cancer 2009, 115, 5596-5606.
2. Basivireddy, J.; Jacob, M.; Balasubramanian, K.A. Oral glutamine attenuates indomethacin-induced small intestinal damage. Clin. Sci. (Lond.) 2004, 107, 281-289.
3. Smets, E.M.; Visser, M.R.; Willems-Groot, A.F.; Garssen, B.; Oldenburger, F.; van Tienhoven, Gde Haes, J.C.; Fatigue and radiotherapy: A experience in patients undergoing treatment. Br. J. Cancer 1998, 78, 899-906.
4. Miaskowski, C.; Paul, S.M.; Cooper, B.A.; Lee, K.; Dodd, M.; West, C.; Aouizerat, B.E.; Swift, P.S.Wara, W.; Trajectories of fatigue in men with prostate cancer before, during, and after radiation therapy. J. Pain Symptom Manage. 2008, 35, 632-643.
5. Saligan, L.N.; Kim, H.S.A systematic review of the association between immunogenomic markers and cancer-related fatigue. Brain. Behav. Immun. 2012, 26, 830-848.
6. Bower, J.E.; Ganz, P.A.; Tao, M.L.; Hu, W.; Belin, T.R.; Sepah, S.; Cole, S.; Aziz, N. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin. Cancer Res. 2009, 15, 5534-5540.
7. Wratten, C.; Kilmurray, J.; Nash, S.; Seldon, M.; Hamilton, C.S.; O'Brien, P.C.;Denham, J.W. Fatigue during breast radiotherapy and its relationship to biological factors. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59, 160-167.
8. Bower, J.E.; Ganz, P.A.; Irwin, M.R.; Kwan, L.; Breen, E.C.; Cole, S.W. Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism? J. Clin. Oncol. 2011, 29, 3517-3522.
9. Liu, L.; Mills, P.J.; Rissling, M.; Fiorentino, L.; Natarajan, L.; Dimsdale, J.E.; Sadler, G.R.; Parker, B.A.; Ancoli-Israel, S.; Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy. Brain. Behav. Immun. 2012, 26, 706-713.
10. Aouizerat, B.E.; Dodd, M.; Lee, K.; West, C.; Paul, S.M.; Cooper, B.A.; Wara, W.; Swift, P.; Dunn, L.B.; Miaskowski, C.; Preliminary Evidence of a Genetic Association Between Tumor Necrosis Factor Alpha and the Severity of Sleep Disturbance and Morning Fatigue. Biol. Res. Nurs. 2009, 11, 27-41.
11. Belloni, P.; Latini, P.; Palitti, F. Radiation-induced bystander effect in healthy G0 human lymphocytes: Biological and clinical significance. Mutat. Res. Fundam. Mol. Mech. Mutagenes. 2011, 713, 32-38.
12. Mariotti, L.G.; Bertolotti, A.; Ranza, E.; Babini, G.; Ottolenghi, A. Investigation of the mechanisms underpinning IL-6 cytokine release in bystander responses: the roles of radiation dose, radiation quality and specific ROS/RNS scavengers. Int. J. Radiat. Biol. 2012, 88, 751-762.
13. York, J.M.; Blevins, N.A.; Meling, D.D.; Peterlin, M.B.; Gridley, D.S.; Cengel, K.A.; Freund, G.G. The biobehavioral and neuroimmune impact of low-dose ionizing radiation. Brain. Behav. Immun. 2012, 26, 218-227.
14. Khayyal, M.T.; El-Ghazaly, M.A.; El-Hazek, R.M.; Nada, A.S. The effects of celecoxib, a COX-2 selective inhibitor, on acute inflammation induced in irradiated rats. Inflammopharmacology 2009, 17, 255-266.
15. Donovan, K.; Jacobsen, P.; Andrykowski, M.; Winters, E.; Balducci, L.; Malik, U.; Kenady, D.; McGrath, P. Course of fatigue in women receiving chemotherapy and/or radiotherapy for early stage breast cancer. J. Pain Symptom Manage. 2004, 28, 373-380.
16. Wright, E.G., Manifestations andmechanisms of non-targeted effects of ionizing radiation. Mutat. Res. Fundam. Mol. Mech. Mutagenes. 2010, 687, 28-33.
17. Medzhitov, R. Origin and physiological roles of inflammation. Nature 2008, 454, 428-435.
18. Wood, L.J.; Nail, L.M.; Perrin, N.A.; Elsea, C.R.; Fischer, A.; Druker, B.J. The Cancer Chemotherapy Drug Etoposide (VP-16) Induces Proinflammatory Cytokine Production and Sickness Behavior-like Symptoms in a Mouse Model of Cancer Chemotherapy-Related Symptoms. Biol.Res. Nurs. 2006, 8, 157-169.
19. Hsiao, C.P.; Wang, D.; Kaushal, A.; Saligan, L. Mitochondria-related gene expression changes are associated with fatigue in patients with nonmetastatic prostate cancer receiving external beam radiation therapy. Cancer Nurs. 2012, 36, 189-197.
20. Saligan, L.N.; Hsiao, C.P.; Wang, D.; Wang, X.M.; John, L.S.; Kaushal, A.; Citrin, D.; Barb, J.J.; Munson, P.J.; Dionne, R.A.; Upregulation of alpha-synuclein during localized radiation therapy signals the association of cancer-related fatigue with the activation of inflammatory and neuroprotective pathways. Brain. Behav. Immun. 2012, 27, 63-70.
21. Yost, K.J.; Eton, D.T.; Garcia, S.F.; Cella, D. Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J. Clin. Epidemiol. 2011, 64, 507-516.
22. Burnette, B.C.; Liang, H.; Lee, Y.; Chlewicki, L.; Khodarev, N.N.; Weichselbaum, R.R.; Fu, Y.X.; Auh, S.L. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res. 2011, 71, 2488-2496.
23. Rosebeck, S.; Leaman, D.W. Mitochondrial localization and pro-apoptotic effects of the interferon-inducible protein ISG12a. Apoptosis 2008, 13, 562-572.
24. Rasmussen, U.B.; Wolf, C.; Mattei, M.-G.; Chenard, M.-P.; Bellocq, J.-P.; Chambon, P.; Rio, M.-C.; Basset, P. Identification of a New Interferon-α-inducible Gene (p27) on Human Chromosome 14q32 and Its Expression in Breast Carcinoma. Cancer Res. 1993, 53, 4096-4101.
25. Kelly, J.M.; Porter, A.C.; Chernajovsky, Y.; Gilbert, C.S.; Stark, G.R.; Kerr, I.M. Characterization of a human gene inducible by alpha- and beta-interferons and its expression in mouse cells. EMBO J. 1986, 5, 1601-1606.
26. Belardelli, F.; Ferrantini, M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 2002, 23, 201-208.
27. Liu, Y.J.; Kanzler, H.; Soumelis, V.; Gilliet, M., Dendritic cell lineage plasticity and cross-regulation. Nat. Immunol. 2001, 2, 585-589.
28. Naing, A.; Reuben, J.M.; Camacho, L.H.; Gao, H.; Lee, B.N.; Cohen, E.N.; Verschraegen, C.; Stephen, S.; Aaron, J.; Hong, D.;et al. Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors. J. Cancer 2011, 2, 81-89.
29. Maher, K.J.; Klimas, N.G.; Fletcher, M.A. Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin. Exp. Immunol. 2005, 142, 505-511.
30. Bower, J.E.; Ganz, P.A.; Aziz, N.; Fahey, J.L. Fatigue AND proinflammatory cytokine activity in breast cancer survivors. Psychosom. Med. 2002, 64, 604-611.
31. Collado-Hidalgo, A.; Bower, J.E.; Ganz, P.A.; Cole, S.W.; Irwin, M.R. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin. Cancer Res. 2006, 12, 2759-2766.
32. Bower, J.E.; Ganz, P.A.; Aziz, N.; Olmstead, R.; Irwin, M.R.; Cole, S.W. Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. Brain. Behav. Immun. 2007, 21, 251-258.
33. Eggermont, A.M.; Suciu, S.; Santinami, M.; Testori, A.; Kruit, W.H.; Marsden, J.; Punt, C.J.; Sales, F.; Gore, M.Mackie, R.;et al; Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008, 372, 117-126.
34. Groenewegen, G.; Walraven, M.; Vermaat, J.; de Gast, B.; Witteveen, E.; Giles, R.; Haanen, J.; Voest, E. Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma. Br. J. Cancer 2012, 106, 284-289.
35. Felger, J.C.; Alagbe, O.; Pace, T.W.; Woolwine, B.J.; Hu, F.; Raison, C.L.; Miller, A.H. Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue. Brain. Behav. Immun. 2011, 25, 1094-1098.
36. Fransson, P.Fatigue in prostate cancer patients treated with external beam radiotherapy: A prospective 5-year long-term patient-reported evaluation. J. Cancer res. Ther. 2010, 6, 516-520.
37. Piper, B.F.; Dibble, S.L.; Dodd, M.J.; Weiss, M.C.; Slaughter, R.E.; Paul, S.M. The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol. Nurs. Forum 1998, 25, 677-684.
38. Byar, K.L.; Berger, A.M.; Bakken, S.L.; Cetak, M.A. Impact of adjuvant breast cancer chemotherapy on fatigue, other symptoms, and quality of life. Oncol. Nurs. Forum 2006, 33, E18-E26.
39. Hays, R.D.; Bjorner, J.B.; Revicki, D.A.; Spritzer, K.L.Cella, D.; Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual. Life Res. 2009, 18, 873-880.
40. Dittner, A.J.; Wessely, S.C.; Brown, R.G. The assessment of fatigue: A practical guide for clinicians and researchers. J. Psychosom. Res. 2004, 56, 157-170.
41. Lydiatt, W.M.; Denman, D.; McNeilly, D.P.; Puumula, S.E.; Burke, W.J., A randomized placebo-controlled trial of citalopram for the prevention of major depression during treatment for head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 2008, 134, 528-535.
42. Wang, X.M.; Wu, T.X.; Hamza, M.; Ramsay, E.S.; Wahl, S.M.; Dionne, R.A. Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain 2007, 128, 136-147.